GS-0976 also reduced levels of a hepatic steatosis and serum fibrosis marker, tissue metalloproteinase inhibitor 1 (TIMP-1), in patients with NASH [27]. Here, TIMP1 is linked to metabolic dysfunction-associated steatohepatitis.